Ghent University Academic Bibliography

Journal Article
A1
open access

Flow cytometry interference in patients treated with tafasitamab : unraveling the diagnostic maze

Lisa Proost, Stijn Lambrecht (UGent) , Mattias Hofmans (UGent) , Ciel De Vriendt (UGent) , Marijn Speeckaert (UGent) , Carolien Bonroy (UGent) , Barbara Denys (UGent) and Sander De Bruyne

(2024) HEMASPHERE. 8(1).

Add to list

Epcoritamab induces deep responses in patients with Richter Transformation (RT) : primary results from the EPCORE CLL-1 trial

Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner (UGent) , Jose D. Sandoval-Sus, Mazyar Shadman, Christian Bjorn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, Marcia Rios, et al.

(2024) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 24(Supplement 1). p.S350-S351

Add to list

Daratumumab (DARA) plus bortezomib/ thalidomide/dexamethasone (D-VTd) followed by DARA maintenance in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM) : 6-year update of the phase 3 CASSIOPEIA study

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Sonja Zweegman, Helene Caillon, Denis Caillot, Herve Avet-Loiseau, et al.

(2024) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 24(Supplement 1). p.S560-S561

Add to list

Clinical outcomes of patients with relapsed/refractory follicular lymphoma (R/R FL) treated with tisagenlecleucel : phase 2 ELARA 3-year follow-up

Stephen J. Schuster, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, et al.

(2024) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 24(Supplement 1). p.S495-S496

Add to list

Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant : CARTITUDE-2 cohort D

Bertrand Arnulf, Tessa Kerre (UGent) , Mounzer Agha, Michel Delforge, Ira Braunschweig, Nishi Shah, Shambavi Richard, Melissa Alsina, Hermann Einsele, Pankaj Mistry, et al.

(2024) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 24(Supplement 1). p.S564-S565

Add to list

Epcoritamab plus R-DHAX/C induces deep, durable responses in transplant-eligible patients with relapsed or refractory (R/R) diffuse large B- cell lymphoma (DLBCL), including high-risk disease

Pau Abrisqueta, Lorenzo Falchi, Marcel Nijland, Sven de Vos, Fritz Offner (UGent) , Ali Rana, Kimberly Archer, Yaou Song, Kojo Osei-Bonsu, Yasmin Karimi, et al.

(2024) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 24(Supplement 1). p.S468-S468

Add to list

Final analysis of the RESONATE-2 study : up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Jan Burger, Paul Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers E. M. Patten, Sebastian Grosicki, Helen McCarthy, Fritz Offner (UGent) , et al.

(2024) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 24(Supplement 1). p.S342-S343

Add to list

Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL) : updated analysis from a phase 1/2 study

Tycel Phillips, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trneny, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner (UGent) , et al.

(2024) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 24(Supplement 1). p.S515-S516

Add to list

Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell Non-Hodgkin lymphoma (LOTIS-7)

Emily C. Ayers, Julien Depaus, Fritz Offner (UGent) , Marie Hu, Craig Okada, Andrzej Urban, Andrew Niewiarowski, Erica Rave, Mary Laughlin and Juan Pablo Alderuccio

(2024) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 24(Supplement 1). p.S474-S474

Add to list

Journal Article
A1
open access

HES6 knockdown in human hematopoietic precursor cells reduces their in vivo engraftment potential and their capacity to differentiate into erythroid cells, B cells, T cells and plasmacytoid dendritic cells

Tamara De Vos (UGent) , Nicole Oatman (UGent) , Lena Boehme (UGent) , Tom Putteman (UGent) , Imke Velghe (UGent) , Yana Van Droogenbroeck (UGent) , Stijn De Munter (UGent) , Michaela Cesnekova (UGent) , Filip Van Nieuwerburgh (UGent) , Bart Vandekerckhove (UGent) , et al.

(2024) HAEMATOLOGICA. 109(11). p.3578-3592

Academic Bibliography

Flow cytometry interference in patients treated with tafasitamab : unraveling the diagnostic maze

Epcoritamab induces deep responses in patients with Richter Transformation (RT) : primary results from the EPCORE CLL-1 trial

Daratumumab (DARA) plus bortezomib/ thalidomide/dexamethasone (D-VTd) followed by DARA maintenance in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM) : 6-year update of the phase 3 CASSIOPEIA study

Clinical outcomes of patients with relapsed/refractory follicular lymphoma (R/R FL) treated with tisagenlecleucel : phase 2 ELARA 3-year follow-up

Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant : CARTITUDE-2 cohort D

Epcoritamab plus R-DHAX/C induces deep, durable responses in transplant-eligible patients with relapsed or refractory (R/R) diffuse large B- cell lymphoma (DLBCL), including high-risk disease

Final analysis of the RESONATE-2 study : up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL) : updated analysis from a phase 1/2 study

Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell Non-Hodgkin lymphoma (LOTIS-7)

HES6 knockdown in human hematopoietic precursor cells reduces their in vivo engraftment potential and their capacity to differentiate into erythroid cells, B cells, T cells and plasmacytoid dendritic cells

Contents

Support

Contact